Filtered By:
Specialty: Practice Management
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 150 results found since Jan 2013.
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
Managing TIA: Early action and essential risk-reduction steps
J Fam Pract. 2022 May;71(4):162-169. doi: 10.12788/jfp.0398.ABSTRACTYour patient with a focal neurologic deficit is rushed to the ED for diagnostic imaging. Which initial and longterm interventions can best reduce their risk of recurrent TIA and stroke?PMID:35730708 | DOI:10.12788/jfp.0398
Source: The Journal of Family Practice - June 22, 2022 Category: Practice Management Authors: Kristen Rundell Shalina Nair Source Type: research
Primary Prevention of CVD with Aspirin: Benefits vs Risks
J Fam Pract. 2021 Jul;70(6S):S41-S46. doi: 10.12788/jfp.0222.ABSTRACTLow-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in the prevention of cardiovascular (CV) events based on the results of large-scale studies supporting a benefit. However, questions remain regarding the benefit-risk relationship in certain settings since long-term use of ASA is not devoid of risk. Incontrovertible evidence supports the benefits of ASA treatment, which exceed the risks, in patients who have had a previous CV event (myocardial infarction, stroke, unstable angina, or transient ischemic attack). Nonetheless, the qu...
Source: The Journal of Family Practice - August 25, 2021 Category: Practice Management Authors: Steven M Weisman Stephen Brunton Source Type: research
